Regeneron Pharmaceuticals, Inc. (REGN) To Go Ex-Dividend on November 20th

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) declared a quarterly dividend on Friday, October 30th. Shareholders of record on Friday, November 20th will be given a dividend of $0.94 per share by the biopharmaceutical company on Thursday, December 3rd. This represents a $3.76 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend is Friday, November 20th.

Regeneron Pharmaceuticals has a dividend payout ratio of 9.6% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect Regeneron Pharmaceuticals to earn $62.79 per share next year, which means the company should continue to be able to cover its $3.76 annual dividend with an expected future payout ratio of 6.0%.

Regeneron Pharmaceuticals Stock Up 0.6%

Shares of REGN opened at $957.76 on Wednesday. The firm has a market cap of $99.08 billion, a PE ratio of 19.94, a price-to-earnings-growth ratio of 1.26 and a beta of 0.10. The company’s fifty day moving average is $821.61 and its two-hundred day moving average is $749.40. Regeneron Pharmaceuticals has a fifty-two week low of $591.52 and a fifty-two week high of $991.73. The company has a quick ratio of 2.89, a current ratio of 3.35 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last announced its quarterly earnings data on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $16.51 by $3.56. The company had revenue of $5.12 billion during the quarter, compared to analysts’ expectations of $4.58 billion. Regeneron Pharmaceuticals had a net margin of 28.51% and a return on equity of 16.01%. The business’s quarterly revenue was up 36.3% compared to the same quarter last year. During the same period in the previous year, the company earned $11.83 EPS. Analysts forecast that Regeneron Pharmaceuticals will post 58.26 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have issued reports on REGN. Royal Bank Of Canada boosted their price target on Regeneron Pharmaceuticals from $810.00 to $913.00 and gave the company a “sector perform” rating in a research report on Monday, November 2nd. Evercore upped their price target on Regeneron Pharmaceuticals from $825.00 to $850.00 and gave the stock an “outperform” rating in a research note on Friday, July 31st. Weiss Ratings upgraded Regeneron Pharmaceuticals from a “hold (c)” rating to a “hold (c+)” rating in a report on Monday, November 2nd. Zacks Research raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, September 28th. Finally, Jefferies Financial Group lifted their price objective on Regeneron Pharmaceuticals from $870.00 to $930.00 and gave the company a “buy” rating in a research note on Thursday, October 1st. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $904.41.

View Our Latest Stock Analysis on REGN

About Regeneron Pharmaceuticals

(Get Free Report)

Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious diseases. Its research and product portfolio spans areas including eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disorders, infectious diseases and rare conditions. The company’s medicines include EYLEA for certain eye diseases, Dupixent for inflammatory conditions and Libtayo for cancer. Regeneron also develops and markets treatments with pharmaceutical partners, including Sanofi, and its products reach patients in the United States and international markets through its own operations and collaborations.

Further Reading

Dividend History for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.